As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.
33 Analysts have issued a Bristol-Myers Squibb forecast:
33 Analysts have issued a Bristol-Myers Squibb forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 48,034 48,034 |
1%
1%
|
|
| Gross Profit | 35,136 35,136 |
2%
2%
|
|
| EBITDA | 20,280 20,280 |
1%
1%
|
|
| EBIT (Operating Income) EBIT | 16,096 16,096 |
45%
45%
|
|
| Net Profit | 6,039 6,039 |
183%
183%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Christopher Boerner |
| Employees | 34,100 |
| Founded | 1933 |
| Website | www.bms.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


